S. Patel

Oncology · The Journal of the National Comprehensive Cancer Network · 2015–2022

A researcher in the Science corpus: 6 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom S. Patel trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll
  2. J. Wolchok
  3. W. Zou
  4. Arlene H. Sharpe
  5. M. Postow
  6. G. Dunn
  7. C. Blank
  8. Lieping Chen
  9. S. Topalian
  10. Janis Taube

Who trusts S. Patel overall

  1. E. Buchbinder

Papers from S. Patel's perspective

Ordered by how strongly the researchers S. Patel trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (Proceedings of the National Academy of Sciences of the United States of America)
  3. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
  4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  5. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  6. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
  7. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)
  8. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
  9. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
  10. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)

Their papers